MedImmune and Advaxis study immuno-oncology combination treatment; MedImmune could get future rights
AstraZeneca PLC’s MedImmune LLC and cancer immunotherapies company Advaxis Inc. will work together to research a new combination therapy consisting of MedImmune’s MEDI4736 and Advaxis’ ADXSHPV aimed at preventing and treating HPV-associated cervical cancer and squamous cell carcinoma of the head and neck.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Trial Collaborations
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.